Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. KEGG DRUG DrugBank Drug (Description in trials) KEGG GENES KEGG PATHWAY Disease ID
1 Elranatamab 💬[1] Elranatamab (ANTI-CD3/ANTI-BCMA BISPECIFIC MONOCLONAL ANTIBODY PF-06863135)[1] Elranatamab[1] CD3E 💬 [11] Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 28 💬
2 Linvoseltamab 💬[1] Linvoseltamab (human IgG4-based anti-CD3 x anti-BCMA bispecific monoclonal antibody that binds to CD3 and BCMA)[1] Linvoseltamab[1] TNFRSF17 💬 [2] Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production 💬[1] 28 💬
3 Mezagitamab 💬[1] Mezagitamab (Anti-Cd38 monoclonal antibody TAK-079)[1] Mezagitamab[1] CD38 💬 [6] Calcium signaling pathway, Hematopoietic cell lineage, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬[2] 63, 66 💬
4 Muromonab-CD3 💬[1] Muromonab (Anti-CD3)[1] ANTI-CD3[3] CD3D,
CD3E,
CD3G 💬 		[11] Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 96 💬